proline has been researched along with glucagon-like peptide 1 in 5 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 2 (40.00) | 24.3611 |
2020's | 2 (40.00) | 2.80 |
Authors | Studies |
---|---|
Bailey, CJ; Flatt, PR; Gault, VA; Green, BD; Greer, B; Harriott, P; Irwin, N; Mooney, MH; O'Harte, FP | 1 |
Gillespie, DG; Jackson, EK; Kochanek, SJ | 1 |
Ardévol, A; Blay, M; González-Abuín, N; Green, BD; Martínez-Micaelo, N; Pinent, M | 1 |
Baek, S; Choi, J; Frias, JP; Muehlen-Bartmer, I; Niemoeller, E; Popescu, L; Rosenstock, J | 1 |
Batra, Y; Jaglan, S; Kaur, B; Rani, S; Singh, P | 1 |
1 trial(s) available for proline and glucagon-like peptide 1
Article | Year |
---|---|
Efficacy and Safety of Once-Weekly Efpeglenatide Monotherapy Versus Placebo in Type 2 Diabetes: The AMPLITUDE-M Randomized Controlled Trial.
Topics: Adult; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Proline; Treatment Outcome | 2022 |
4 other study(ies) available for proline and glucagon-like peptide 1
Article | Year |
---|---|
Metabolic stability, receptor binding, cAMP generation, insulin secretion and antihyperglycaemic activity of novel N-terminal Glu9-substituted analogues of glucagon-like peptide-1.
Topics: Adenosine Deaminase; Amino Acid Substitution; Animals; Binding, Competitive; Blood Glucose; Cell Line, Tumor; Cricetinae; Cyclic AMP; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Fibroblasts; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucose; Glutamine; Glycoproteins; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Islets of Langerhans; Mice; Mice, Obese; Peptide Fragments; Phenylalanine; Proline; Protein Precursors; Rats; Receptors, Glucagon; Spectrometry, Mass, Electrospray Ionization; Transformation, Genetic; Tyrosine | 2003 |
Dipeptidyl peptidase IV regulates proliferation of preglomerular vascular smooth muscle and mesangial cells.
Topics: Animals; Arginine; Cell Proliferation; Cells, Cultured; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Glomerular Mesangium; Glucagon-Like Peptide 1; Male; Models, Animal; Muscle, Smooth, Vascular; Neuropeptide Y; Peptide Fragments; Peptide YY; Proline; Pyrazines; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Sitagliptin Phosphate; Thymidine; Triazoles | 2012 |
Grape-seed procyanidins modulate cellular membrane potential and nutrient-induced GLP-1 secretion in STC-1 cells.
Topics: Animals; Cell Line; Cell Line, Tumor; Cell Membrane; Dose-Response Relationship, Drug; Enteroendocrine Cells; Food-Drug Interactions; Glucagon-Like Peptide 1; Glucose; Grape Seed Extract; Linoleic Acid; Membrane Potential, Mitochondrial; Membrane Potentials; Mice; Proanthocyanidins; Proline; Time Factors | 2014 |
Proline based rationally designed peptide esters against dipeptidyl peptidase-4: Highly potent anti-diabetic agents.
Topics: Blood Glucose; Dipeptidyl-Peptidase IV Inhibitors; Drug Design; Esters; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Hypoglycemic Agents; Oligopeptides; Proline; Sitagliptin Phosphate | 2022 |